Actively Recruiting
Study of Tegavivint IV Infusions in Children and Young Adults with Recurrent or Refractory Solid Tumors Including Lymphomas and Desmoid Tumors
Led by Children's Oncology Group · Updated on 2026-08-25
147
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying tegavivint, a drug given intravenously, in children and young adults aged 1 to 30 years with solid tumors that have returned or do not respond to treatment. These tumors include types such as non-Hodgkin lymphoma, desmoid tumors, Ewing sarcoma, liver tumors, osteosarcoma, Wilms tumor, and tumors involving the Wnt pathway. The study aims to find the safest dose, side effects, and how well tegavivint works to stop tumor growth by blocking signals inside cells that promote growth. Participants receive tegavivint as a four-hour intravenous infusion on days 1, 8, and 15 of each 28-day cycle. Treatment can continue for up to 26 cycles or 24 months if the disease does not worsen and side effects are acceptable. Dosage is adjusted by weight, with starting doses of 5 mgkg and potential increases if tolerated. Patients also have x-rays and DEXA scans at scheduled times during and after treatment. Blood samples are collected throughout the trial to study the drugs effects. During the study, participants undergo regular imaging and lab tests to monitor disease and side effects. After finishing treatment, they have follow-up visits every 3 months for 12 months, every 6 months for 24 months, then annually up to 5 years to track long-term safety and outcomes. The main measures include tracking side effects, drug levels in the blood, and tumor responses. This helps researchers understand both the safety and initial effectiveness of tegavivint for these difficult-to-treat cancers.
CONDITIONS
Brief Title
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here